In a key decision, the Centers for Medicare and Medicaid Services (CMS) said today that Medicare will not pay for the controversial Alzheimer’s drug Adulhelm until it sees positive results from a government-approved trial.
Subscribe to:
Post Comments (Atom)
< + > From Fragmented Data to Actionable Intelligence
Modern tools, including AI, offer healthcare institutions new windows onto their data with the potential for real business changes. In our r...
No comments:
Post a Comment